User profiles for STEVEN P. ROWE

Steven P. Rowe

University of North Carolina
Verified email at med.unc.edu
Cited by 11255

Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial

…, N Radwan, SJ Lim, ES Antonarakis, SP Rowe… - JAMA …, 2020 - jamanetwork.com
Importance Complete metastatic ablation of oligometastatic prostate cancer may provide an
alternative to early initiation of androgen deprivation therapy (ADT). Objective To determine …

Molecular imaging in oncology: Current impact and future directions

SP Rowe, MG Pomper - CA: a cancer journal for clinicians, 2022 - Wiley Online Library
The authors define molecular imaging, according to the Society of Nuclear Medicine and
Molecular Imaging, as the visualization, characterization, and measurement of biological …

[HTML][HTML] Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer

Z Szabo, E Mena, SP Rowe, D Plyku, R Nidal… - Molecular imaging and …, 2015 - Springer
Purpose Prostate-specific membrane antigen (PSMA) is a recognized target for imaging
prostate cancer. Here we present initial safety, biodistribution, and radiation dosimetry results …

Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study

MJ Morris, SP Rowe, MA Gorin, L Saperstein… - Clinical Cancer …, 2021 - AACR
… MJ Morris and SP Rowe contributed equally to this article. … SP Rowe reports grants from
Progenics Pharmaceuticals during the conduct of the study, as well as personal fees from …

[HTML][HTML] E-PSMA: the EANM standardized reporting guidelines v1. 0 for PSMA-PET

…, MS Hofman, TA Hope, R Kumar, SP Rowe… - European journal of …, 2021 - Springer
Rationale The development of consensus guidelines for interpretation of Prostate-Specific
Membrane Antigen (PSMA)-Positron Emission Tomography (PET) is needed to provide more …

A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients …

KJ Pienta, MA Gorin, SP Rowe, PR Carroll… - The Journal of …, 2021 - auajournals.org
Purpose: Prostate specific membrane antigen-targeted positron emission tomography/computerized
tomography has the potential to improve the detection and localization of prostate …

[HTML][HTML] Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)

R Seifert, L Emmett, SP Rowe, K Herrmann… - European Urology, 2023 - Elsevier
Context Prostate-specific membrane antigen (PSMA) targeting positron emission tomography
(PET) is emerging to become a reference imaging tool for the staging and restaging of …

PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer

SP Rowe, KJ Macura, E Mena, AL Blackford… - Molecular imaging and …, 2016 - Springer
Purpose Current standard of care conventional imaging modalities (CIM) such as X-ray
computed tomography (CT) and bone scan can be limited for detection of metastatic prostate …

Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging

…, U Haberkorn, MG Pomper, MA Gorin, SP Rowe - European journal of …, 2017 - Springer
Background The rapidly expanding clinical adaptation of prostate-specific membrane
antigen (PSMA)-targeted PET imaging in the evaluation of patients with prostate cancer has …

18F-DCFBC PET/CT for PSMA-based detection and characterization of primary prostate cancer

SP Rowe, KL Gage, SF Faraj, KJ Macura… - Journal of Nuclear …, 2015 - Soc Nuclear Med
We previously demonstrated the ability to detect metastatic prostate cancer using N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-
18 F-fluorobenzyl-l-cysteine ( 18 F-DCFBC), a low-…